Jefferies analyst Benjamin Jackson CFA has maintained their bullish stance on GALD stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Benjamin Jackson CFA’s rating is based on several strategic developments involving Galderma Group AG and L’Oreal. L’Oreal’s decision to increase its stake in Galderma to 20% signifies a strong vote of confidence in the company’s potential, especially in the fast-growing aesthetics market. This investment not only strengthens L’Oreal’s position but also suggests a deeper collaboration between the two companies, as Galderma considers nominating board members from L’Oreal to enhance business understanding and integration.
Additionally, the ongoing R&D partnership between Galderma and L’Oreal, with a focus on current diagnostic research projects, indicates a commitment to innovation and growth. These factors collectively suggest a positive outlook for Galderma, leading Benjamin Jackson CFA to recommend a Buy rating, reflecting the anticipated benefits from these strategic moves and the potential for future value creation.
According to TipRanks, Jackson CFA is a 3-star analyst with an average return of 12.2% and a 60.00% success rate. Jackson CFA covers the Healthcare sector, focusing on stocks such as Galderma Group AG, Roche Holding AG, and Sanofi.
In another report released today, Barclays also maintained a Buy rating on the stock with a CHF155.00 price target.